Canadian clinical trial registry

Go to Health Care Provider version

Centres

Study Description

This study will explore the safety, tolerability and efficacy of the biologic CC-96191 in acute myeloid leukemia (AML) that has come back or not responded to previous treatment. 

Inclusion Criteria

• Patient must be 18 years or older
• Patient must have AML that has come back (relapsed) or not responded to previous treatment
• Patient must be willing to sign a consent form
• Females and males must practice true abstinence or agree to approved contraceptive methods throughout the study, and during the safety follow-up period.

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

Go to Health Care Provider version

Centres

Study Description

This study is aimed at improving the outcome for children with High Grade Glioma (HGG). Temozolomide, a medication taken by mouth, has been shown to improve survival in adults with glioblastoma, when taken during and after radiation. In this study, patients with a HGG that has specific molecular features (wild-type for H3-K27, IDH and BRAF) will receive experimental therapy of veliparib (given by mouth) during radiation therapy, followed by veliparib in combination with temozolomide.

This study will test whether this combination therapy may improve survival in children with newly diagnosed HGG that are wild-type for H3-K27, IDH and BRAF. Patients with IDH mutant glioma are also eligible. The outcomes of patients on this study will be compared to other patients with clinically and molecularly similar HGG treated with temozolomide alone.

(Retrieved from: https://www.childrensoncologygroup.org/acns1721)

Inclusion Criteria

• Patients must be at least 3 years old and less than 22 years of age. Patients less than 25 years old may be eligible to enroll if they have a specific type of high grade glioma
• Patients must have newly diagnosed High Grade Glioma, that does not include brainstem or spinal cord tumors, or disease that has spread to other parts of the body (metastatic disease)
• Patients must agree to the study activities outlined in the consent forms; including MRI's, blood tests, biopsies etc - as they apply
• Patients must be able to walk and do routine activities for more than half of their normal waking hours
• If the patient has a seizure disorder, they may be enrolled if the seizures are well-controlled
• A written consent form must be signed by the patients and/or their parents/legal guardians

Other inclusion and exclusion criteria may apply and will be discussed with you by the study doctor.

Go to Health Care Provider version

Centres

Study Description

This study is to assess the effectiveness of molecular targeted therapy (four different possible medications) in addition to standard therapy for patients with a new diagnosis of high-risk neuroblastoma. The study also looks at the side effects associated with these medications.

The study also tests the effects of a drug called DFMO when added to the immunotherapy given as post-consolidation treatment.

Inclusion Criteria

• Age 1 to 22 years
• New diagnosis of high risk neuroblastoma
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

This is a Phase 2 trial for newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of combining the drug naxitamab with standard induction therapy. Initially, there will be 5 cycles of standard chemotherapy with Naxitamab on days 1, 3 and 5 of each cycle. Patients with an ALK mutation or amplification will have the drug ceritinib added to their treatment regimen as soon as results are available. 

Inclusion Criteria

• Subjects must have a diagnosis of neuroblastoma or ganglioneuroblastoma that meets criteria
• Subjects must be age ≤ 21 years at initial diagnosis
• Subjects must be >12 months of age at enrollment
• Subject's bloodwork must be within acceptable study ranges
• Pregnant subjects are not eligible for this study, a negative serum pregnancy test is required for female participants of childbearing potential
• Both male and female study subjects who have reached puberty must be willing to use a highly effective contraceptive method, these methods will be discussed with you by the study team
• All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines.
• Subjects enrolled on study must complete all required assessments 

Go to Health Care Provider version

Centres

Study Description

This trial studies the combination of a study drug called palbociclib with chemotherapy in children with solid tumors that have come back or not responded to standard treatment. Throughout this trial, the study team will observe how the drug is moving through your body and how your body is responding to the drug. The study team will also do a series of tests to study whether or not the drug is effective.

Inclusion Criteria

• Patient must be between 2 years to 20 years old at time of treatment
• Must have measurable disease of a solid tumour that has come back or has not responded to previous standard treatment 
  • For Phase 2 part, must have a diagnosis of Ewing sarcoma specifically 
• Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other procedures related to the study
• Patient must be able to be up and about more than 50% of their waking hours
• For patients of child bearing potential, they must not be pregnant or get pregnant during the course of the study

Other inclusion and exclusion criteria may apply and will be reviewed by your team

Go to Health Care Provider version

Centres

Study Description

This study is to assess the effectiveness of a drug called Difluoromethylornithine (DFMO) in combination with etoposide for patients with neuroblastoma that has come back, or is not responidng to current treatment. DFMO is a medication taken by mouth. It is an blocker of ornithine decarboxylase, an enzyme involved with polyamine biosynthesis in the cancer cells, including neuroblastoma cells. 

Inclusion Criteria

• Patients less than 31 years of age 
• Diagnosis of neuroblastoma that has come back or is not responding to treatment 
• Patients can have active or no active disease at the time of study start
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

This phase II trial studies how well the drug nirogacestat works in treating patients between the age of 1 to 18 years old with desmoid tumours that have grown after prior treatment and that cannot be removed by surgery. Nirogacestat works by blocking some of the chemicals that play a role in the growth of tumor cells. 

Inclusion Criteria

• Patient must have a desmoid tumor that is existing or that has come back (recurrent) and that cannot be removed by surgery
• Patients must be between 12 months to 18 years old 
• At minimum, patients must be up and about at least 50% of their waking hours 
• Blood work must come back within the acceptable ranges
• Patients must have adequate heart function 
• All patients and/or their parents or legal guardians must sign a written informed consent
• Your study doctor will discuss with you the medications you can and cannot take

Other inclusion and exclusion criteria may apply 

Go to Health Care Provider version

Centres

Study Description

This study uses a drug called Difluoromethylornithine (DFMO) for patients with neuroblastoma in remission to assess the effectiveness of preventing recurrence. The study also looks at the side effects associated with these medication. DFMO is a medication taken by mouth. It is an blocker of ornithine decarboxylase, an enzyme involved with polyamine biosynthesis in the cancer cells, including neuroblastoma cells. 

Inclusion Criteria

• Patients less than 30 years of age, with high-risk neuroblastoma in complete remission.